Your gift is 100% tax deductible
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Your gift enables us to support people with cancer and fund research breakthroughs.
The amount must be greater than or equal to $5
Your gift is 100% tax deductible
When biopsy samples are collected from your prostate, they are studied by a doctor with special training, called a pathologist. After testing the samples, the pathologist creates a report on what was found. Your doctor can use this report to help manage your care.
The information here is meant to help you understand some of the medical terms you might see in your pathology report after your prostate is biopsied.
The most common type of prostate biopsy is a core needle biopsy. For this procedure, the doctor inserts a thin, hollow needle into the prostate gland. When the needle is pulled out it removes a small cylinder of prostate tissue, which is called a core. The doctor will typically remove cores from several different areas of the prostate during a biopsy.
The pathologist will give each core (biopsy sample) a number (or letter) in your pathology report, and each core will get its own diagnosis . If cancer or some other problem is found, it is often not in every core, so you need to look at the diagnoses for all of the cores to know what's going on.
Sometimes when looking at a biopsy sample with a microscope, the pathologist sees cells that might be cancer, but there are too few of them to be sure. A finding like this might be described as:
A lot of things that can be seen under the microscope are not cancer but can look like cancer, so the pathologist has to be very cautious when diagnosing prostate cancer, especially on a small biopsy sample.
Still, having an atypical or suspicious finding on your prostate biopsy could mean you have prostate cancer that the biopsy missed. Overall, if 100 men with an atypical or suspicious finding had a second biopsy, cancer would be found in about 40 to 50 of them.
Because of this risk, close follow up after an atypical or suspicious finding is important. Most doctors will recommend getting another prostate biopsy within 3 to 6 months. Another option might be close follow up with blood, urine, or imaging tests. One reason that another biopsy is not always done is because most cancers that are found after an “atypical” finding on a biopsy are not life threatening.
If you have an atypical or suspicious finding on your biopsy, talk to your doctor about if and when you should have another biopsy.
High-grade prostatic intraepithelial neoplasia (high-grade PIN) is considered a pre-cancer of the prostate, because sometimes it can turn into prostate cancer over time.
While high-grade PIN increases your risk of having prostate cancer, this risk is not nearly as high as if your biopsy report mentions findings that are atypical or suspicious for cancer. Therefore, if you have both, the atypical or suspicious findings on your biopsy are more important, as they have a greater impact on your cancer risk and future care.
Inflammation of the prostate is called prostatitis. (Acute means it started recently, whereas chronic means it’s been going on for a while.)
Prostate inflammation can have different causes. Most often, prostatitis reported on biopsy is not caused by infection and does not need to be treated.
Inflammation (especially acute inflammation) might raise your prostate-specific antigen (PSA) blood level, but it is not linked to prostate cancer.
All of these are benign (not cancer) conditions the pathologist might see under the microscope, but that can sometimes look like cancer.
Atrophy is a term used to describe a shrinkage of prostate tissue.
Atypical adenomatous hyperplasia (sometimes called adenosis) is another benign condition that can sometimes be seen on a prostate biopsy.
The seminal vesicles are glands that lie just behind the prostate. Sometimes part of a seminal vesicle is sampled during a biopsy. This is not a cause for concern.
If the pathologist sees cells in the biopsy samples that might be cancer, different types of lab tests might be done to help tell if they are cancer cells. These tests are often immunohistochemical (IHC) stains done on very thin slices of biopsy samples, which are placed on glass slides and viewed under a microscope. Sometimes other types of tests are done as well.
Some of the tests that might be done include:
All of these tests can be used to help diagnose prostate cancer. But not everyone needs these tests, so whether or not your report mentions these tests has no effect on the accuracy of your diagnosis.
Unfortunately, even with these tests, a biopsy diagnosis of atypical or suspicious findings means that it isn’t clear if cancer is present or absent.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Last Revised: July 7, 2023
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.